Top CGM Brands: Leading the Future of Health Monitoring

Continuous Glucose Monitors (CGMs) have revolutionized diabetes management by offering real-time glucose monitoring, allowing users to make informed decisions about their health. Among the top choices in the market, several brands stand out for their innovation, reliability, and user-friendly features. With each brand offering unique benefits, from long sensor wear time to easy integration with smartphone apps, CGMs cater to diverse needs and preferences. For those interested in finding the best CGM brand for themselves, explore the detailed insights provided below.

Illustration of cgm

Best brands of cgm in 2025

Dexcom

Dexcom is a leading producer of continuous glucose monitoring (CGM) systems, known for its innovative and accurate technologies. In 2023, the company achieved significant growth, with a 25% revenue increase driven by international market share gains and a 21% sales growth in the U.S., fueled by the successful launch of the Dexcom G7 in over 15 international markets. The G7 system is recognized for its real-time glucose insights and is designed for adults and children with diabetes, offering unparalleled accuracy and convenience. Dexcom's revenue for 2023 reached approximately $3.62 billion, a 24% increase over 2022, with expectations of further growth in 2024 to $4.15 billion to $4.35 billion. The company continues to expand its market, including the upcoming launch of Stelo, a glucose sensor for people with type 2 diabetes who do not use insulin. For more information, visit Dexcom's official website.

Abbott

Abbott's FreeStyle Libre is renowned as one of the most successful medtech products in history, with over 5 million users worldwide and 2 million in the United States. It has achieved impressive annual sales of roughly $5 billion and is projected to reach $10 billion by 2028, representing a compound annual growth rate of about 15%. The FreeStyle Libre 2 and 3 systems are the first CGM sensors approved for use during common imaging procedures like X-rays, CT scans, and MRIs. Abbott dominates the market share among people with Type 2 diabetes and is expanding its reach through strategic partnerships with insulin pump makers. By 2030, it is estimated that over half of people with Type 2 diabetes taking basal insulin will use a CGM, underlining Abbott’s pivotal role in transforming diabetes management.

Medtronic

Medtronic is a leading producer of continuous glucose monitoring (CGM) systems, known for its innovative technologies such as the Guardian 4 sensor and the MiniMed 780G insulin pump. Despite facing declining U.S. market share since 2019, Medtronic's global diabetes sales are significant, with the U.S. market accounting for about 38% of its total diabetes sales. The company has recently had its warning letter lifted by the FDA and has received approval for its new insulin pump, indicating potential for market share recovery. Medtronic's CGM systems, such as the Guardian 4, offer advanced features like predictive low glucose alerts and seamless integration with insulin pumps. The company continues to invest heavily in its diabetes care business, with multiple programs under development to restore strong growth.

Eversense

Eversense, developed by Senseonics, stands out as a leading producer of continuous glucose monitoring (CGM) systems, offering the only CGM that lasts up to a year, such as the Eversense 365. This innovative device provides real-time glucose readings with minimal device frustrations and requires calibration only once a week, a significant improvement over the 180-day version that needed calibration twice a day. Senseonics forecasts significant growth, expecting global net revenues to increase by 22% to 46% in 2023 and aiming to double sales in 2025 to $100 million to $120 million. The company is also working towards capturing 5% of the CGM market by 2027, with a goal of growing global Eversense sales to over $500 million. With its favorable Medicare coverage and a clean path to reimbursement, Eversense is poised to expand its user base and integrate with other diabetes management devices.

Tandem Diabetes Care

Tandem Diabetes Care is a leading producer in the continuous glucose monitoring (CGM) and insulin delivery market, known for its innovative and user-centric approach. The company's flagship product, the t:slim X2 insulin pump, is the smallest durable insulin pump available and features integrated CGM technology, including recent integration with Dexcom G7 CGM sensors. Tandem has seen significant growth, with a 13% increase in worldwide GAAP sales in the second quarter of 2024 and a projected customer base of 1 million by 2027. The company's products are designed for remote software updates, enhancing the user experience and future-proofing their devices. Tandem's collaboration with Abbott to integrate glucose-sensing technology further expands their offerings for diabetes management. For more information about Tandem Diabetes Care, visit their official website.

Glooko

Glooko is a leading brand in diabetes data management, particularly renowned for its integration with Continuous Glucose Monitoring (CGM) and insulin pump data. The platform is used by over 1.5 million people with diabetes and more than 7,000 provider sites, including major health systems like Fairview Hospitals and the University of Colorado. Glooko's CGM data features are highly valued by clinicians, with over 70% using three or more features to assess glycemic control, highlighting the importance of metrics like hypoglycemia and variance. The company has demonstrated significant clinical outcomes, such as an 18% reduction in average blood glucose and a 0.8 point reduction in HbA1c within three months. Glooko's solutions are trusted globally, operating in over 30 countries and managing over 100 billion health data points.

WaveForm Technologies

WaveForm Technologies is renowned for its innovative Continuous Glucose Monitoring (CGM) solutions, having developed the Cascade CGM system that received a European CE mark in 2019. This technology features needle-free insertion, reducing pain and trauma, and a reusable applicator and transmitter, which lowers production costs and biological waste. WaveForm's CGM assets were acquired by Trinity Biotech in January 2024 for $12.5 million in cash, 9 million American Depositary Shares, and additional contingent consideration. The acquired technology is set to be integrated into Trinity's AI-driven health and wellness platform, enhancing its CGM offerings. This partnership aims to make CGM more accessible and financially viable for broader markets. For more details, read the full Trinity Biotech announcement regarding the acquisition.

Ascensia Diabetes Care

Ascensia Diabetes Care is a leading global company dedicated to improving the lives of people with diabetes, particularly through its innovative Continuous Glucose Monitoring (CGM) systems. Established in 2016 following the acquisition of Bayer Diabetes Care by Panasonic Healthcare Holdings, Ascensia brings over 80 years of experience in diabetes care. The company is the exclusive global distribution partner for the Eversense® CGM Systems, the first and only long-term implantable sensor. Ascensia's products, including the CONTOUR™ portfolio, are renowned for their advanced technology and user-friendly functionality, aiding patients in managing their condition effectively. With a strong presence in the North America CGM market, Ascensia is among the key players, alongside Dexcom, Medtronic, and Abbott, contributing to the market's significant growth, which is expected to reach USD 17.61 billion by 2029.

Roche Diabetes Care

Roche Diabetes Care, through its Accu-Chek Smartguide, has entered the competitive continuous glucose monitoring (CGM) market with a device that leverages AI-based predictive algorithms to forecast glucose levels up to two hours in advance and warn of potential hypoglycemia within 30 minutes. This innovation aims to address persistent glycemic control issues and reduce the fear of hypoglycemia, particularly beneficial for patients with Type 1 and Type 2 diabetes. Despite being a late entrant, Roche's CGM has gained a CE mark, enabling its sale in selected European markets. The global CGM market, which includes players like Abbott and Dexcom, is expected to grow at a CAGR of 6.60% from 2021 to 2027, with sales projected to reach $6.7 billion by 2033. Roche's device, though requiring finger stick calibration, offers advanced digital solutions and integrated care through its Personalised Diabetes Management (iPDM) approach. Learn more about Roche's innovative diabetes management solutions on their official website.

Ypsomed

Ypsomed, although not primarily a continuous glucose monitoring (CGM) device producer, has made significant strides in the diabetes care sector, particularly with its mylife YpsoPump and mylife Loop solutions. The mylife Loop, an innovative system for automated insulin delivery, has reached around 60,000 active users by the end of September 2024, primarily in Germany, France, the UK, Australia, and Spain. Ypsomed's Diabetes Care business area achieved a 51.3% growth in the first half of 2024/25, despite plans to initiate its sale. The company's focus on expanding its leading position in the Delivery Systems division is driven by strong growth in self-medication and the rise of biologics and biosimilars. Ypsomed's market share in the pump market in Germany has grown substantially to around 16%. For more detailed information, visit their official media release.